PKC-IN-1 |
Katalog-Nr.GC31711 |
PKC-IN-1 ist ein potenter, ATP-kompetitiver und reversibler Inhibitor herkÖmmlicher PKC-Enzyme mit Kis von 5,3 und 10,4 nM fÜr humane PKCβ und PKCα und IC50-Werten von 2,3, 8,1, 7,6, 25,6, 57,5, 314, 808 nM fÜr PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu bzw. PKCε.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1046787-18-1
Sample solution is provided at 25 µL, 10mM.
PKC-IN-1 is a potent, ATP-competitive and reversible inhibitor of conventional PKC enzymes with Kis of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC50s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε, respectively.
PKC-IN-1 (Compound A) is a potent, ATP-competitive and reversible of conventional PKC enzymes with Kis of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC50s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε, respectively[1].
PKC-IN-1 (Compound A; 15 and 30 mg/kg, p.o., bid (twice a day)) dose-dependently and significantly reduces maximum EAE severity and end severity in autoimmune encephalitis (EAE) model in Lewis rats[1].
[1]. Michael Niesman, et al. Treatment of autoimmune disease. WO2015179847A1.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *